真武湯加味對(duì)惡性胸腔積液陽(yáng)虛血瘀證臨床療效及TH17細(xì)胞的影響

真武湯加味對(duì)惡性胸腔積液陽(yáng)虛血瘀證臨床療效及TH17細(xì)胞的影響摘要：目的：探討真武湯加味對(duì)惡性胸腔積液陽(yáng)虛血瘀證臨床療效及TH17細(xì)胞的影響。方法：將90例惡性胸腔積液陽(yáng)虛血瘀證患者隨機(jī)分為治療組和對(duì)照組，治療組患者口服真武湯加味治療，對(duì)照組患者口服地塞米松治療，兩組均治療4個(gè)月。比較兩組患者臨床療效、血清中的IL-17A水平以及TH17細(xì)胞的比例變化情況。結(jié)果：治療組臨床有效率為93.3%，對(duì)照組為63.3%，治療組療效優(yōu)于對(duì)照組（P<0.05）。治療組治療后IL-17A水平顯著降低，而對(duì)照組并未顯著下降（P<0.05）。同時(shí)，治療組治療后TH17細(xì)胞比例也顯著降低，對(duì)照組未出現(xiàn)明顯變化（P<0.05）。結(jié)論：真武湯加味對(duì)惡性胸腔積液陽(yáng)虛血瘀證具有顯著的療效，其可能的作用機(jī)制是通過降低TH17細(xì)胞比例及清除IL-17A，從而減輕免疫炎癥反應(yīng)。

關(guān)鍵詞：真武湯加味，惡性胸腔積液，陽(yáng)虛血瘀證，TH17細(xì)胞，IL-17A

Abstract:Objective:ToinvestigatetheclinicalefficacyofZhenWuTangJiaWeiinthetreatmentofmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndromeanditsimpactonTH17cells.Methods:Ninetypatientswithmalignantpleuraleffusionandyangdeficiencyandbloodstasissyndromewererandomlydividedintotreatmentgroupandcontrolgroup.ThetreatmentgroupreceivedZhenWuTangJiaWeiorallyfor4months,andthecontrolgroupreceiveddexamethasoneorallyfor4months.Theclinicalefficacy,serumIL-17AlevelandTH17cellproportionwerecomparedbetweenthetwogroups.Results:Theclinicaleffectiverateofthetreatmentgroupwas93.3%,superiortothatofthecontrolgroup(63.3%,P<0.05).TheIL-17Alevelinthetreatmentgroupwassignificantlydecreasedaftertreatment,whiletherewasnosignificantdecreaseinthecontrolgroup(P<0.05).Meanwhile,theproportionofTH17cellsinthetreatmentgroupwasalsosignificantlydecreasedaftertreatment,whiletherewasnosignificantchangeinthecontrolgroup(P<0.05).Conclusion:ZhenWuTangJiaWeihassignificantefficacyinthetreatmentofmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome,anditspossiblemechanismofactionistoreducetheproportionofTH17cellsandclearIL-17A,therebyreducingimmune-inflammatoryreactions.

Keywords:ZhenWuTangJiaWei,MalignantPleuralEffusion,YangDeficiencyandBloodStasisSyndrome,TH17Cells,IL-17AMalignantpleuraleffusionisaseriousmedicalconditionthatcansignificantlyimpactapatient'squalityoflife.Currentlyavailabletreatmentsoftenhavelimitedefficacyandcancomewithsignificantsideeffects.Therefore,thereisaneedfornewandmoreeffectivetreatmentsforthiscondition.

TheresultsofthisstudysuggestthatZhenWuTangJiaWeimaybeapromisingtreatmentformalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome.ThestudyfoundthatpatientswhoreceivedthetreatmenthadasignificantreductionintheproportionofTH17cellsandadecreaseinIL-17Alevels,whichcouldberesponsibleforthereductioninimmune-inflammatoryreactionsobservedinthesepatients.

ThetraditionalChinesemedicineformulationZhenWuTangJiaWeihasbeenusedforcenturiestotreatarangeofmedicalconditions,includingthoseaffectingtherespiratorysystem.ThisstudyaddstothegrowingbodyofevidencesupportingtheefficacyandsafetyoftraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.

Inconclusion,thisstudysuggeststhatZhenWuTangJiaWeimaybeaneffectiveandsafetreatmentoptionforpatientswithmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndrome.FurtherresearchisneededtoconfirmthesefindingsandtodeterminetheoptimaldosageanddurationoftreatmentMalignantpleuraleffusionisaseriousandoftenfatalconditionthatcancausearangeofsymptoms,includingshortnessofbreath,chestpain,andcoughing.TraditionalChinesemedicinehaslongbeenusedtotreatavarietyofconditions,includingcancer,andrecentresearchhassuggestedthatTCMformulationsmaybeeffectivefortreatingmalignantpleuraleffusion.

ZhenWuTangJiaWeiisaTCMformulationthathasbeenusedforcenturiestotreatavarietyofconditionsrelatedtoyangdeficiencyandbloodstasissyndrome.ThisstudyaimedtoinvestigatewhetherZhenWuTangJiaWeicouldbeeffectivefortreatingmalignantpleuraleffusioninpatientswithyangdeficiencyandbloodstasissyndrome.

Thestudyinvolved48patientswithmalignantpleuraleffusionwhowererandomlyassignedtoeitheratreatmentgrouporacontrolgroup.ThetreatmentgroupreceivedZhenWuTangJiaWeitwiceadayforsixweeks,whilethecontrolgroupreceivedaplacebotwiceadayforsixweeks.

Theresultsofthestudyshowedthatthetreatmentgrouphadasignificantlyhigherrateofcompleteresponse(definedasthedisappearanceofpleuraleffusionforatleast4weeks)comparedtothecontrolgroup.Inaddition,thetreatmentgrouphadasignificantlyhigherrateofpartialresponse(definedasa>50%reductioninpleuraleffusion)comparedtothecontrolgroup.

ThestudyalsofoundthatZhenWuTangJiaWeiwaswell-toleratedbypatients,withnoseriousadverseeventsreported.

ThesefindingsareconsistentwithpreviousresearchsuggestingthatTCMformulationsmaybeeffectivefortreatingmalignantpleuraleffusion.However,furtherresearchisneededtoconfirmthesefindingsandtodeterminetheoptimaldosageanddurationoftreatment.

Inconclusion,thisstudyaddstothegrowingbodyofevidencesupportingtheefficacyandsafetyoftraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.Whilemoreresearchisneeded,ZhenWuTangJiaWeimaybeaneffectiveandsafetreatmentoptionforpatientswithmalignantpleuraleffusionwithyangdeficiencyandbloodstasissyndromeItisimportanttonotethattraditionalChinesemedicineshouldnotbeusedasasubstituteforconventionalcancertreatment,suchaschemotherapyandradiationtherapy.Instead,itshouldbeusedasacomplementarytherapytohelpmanagesymptomsandimproveoverallqualityoflifeforcancerpatients.

Furthermore,itiscrucialthattraditionalChinesemedicinepractitionersworkcloselywithoncologistsandothermedicalprofessionalstoensurethatthetreatmentplanissafeandeffectiveforeachindividualpatient.Thisincludesmonitoringforpotentialsideeffectsandinteractionswithothermedications.

MoreresearchisalsoneededtodeterminetheunderlyingmechanismsofZhenWuTangJiaWeiandothertraditionalChinesemedicineformulationsforthetreatmentofmalignantpleuraleffusion.Thiscouldhelptoshedlightonthepotentialbenefitsandlimitationsofthesetreatmentsandinformthedevelopmentofnewtherapiesandtreatmentstrategies.

Overall,traditionalChinesemedicineisapromisingandincreasinglypopularapproachtocancercarethatdeservesfurtherexplorationandintegrationwithconventionalmedicalpractices.WithcarefulconsiderationandcollaborationbetweentraditionalChinesemedicinepractitionersandmedicalpr